Koichi Azuma

13.8k total citations · 2 hit papers
266 papers, 6.2k citations indexed

About

Koichi Azuma is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Koichi Azuma has authored 266 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Oncology, 150 papers in Pulmonary and Respiratory Medicine and 43 papers in Molecular Biology. Recurrent topics in Koichi Azuma's work include Lung Cancer Treatments and Mutations (136 papers), Lung Cancer Research Studies (60 papers) and Cancer Immunotherapy and Biomarkers (52 papers). Koichi Azuma is often cited by papers focused on Lung Cancer Treatments and Mutations (136 papers), Lung Cancer Research Studies (60 papers) and Cancer Immunotherapy and Biomarkers (52 papers). Koichi Azuma collaborates with scholars based in Japan, United States and United Kingdom. Koichi Azuma's co-authors include Akihiko Kawahara, Tomoaki Hoshino, Satoshi Hattori, Masayoshi Kage, Isamu Okamoto, Yoichi Nakanishi, Shinzo Takamori, Eiji Iwama, Hidenobu Ishii and Kazuhiko Yamada and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Koichi Azuma

255 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

2014 525 citations Koichi Azuma, Keiichi Ota et al. profile →
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

2015 366 citations Keiichi Ota, Koichi Azuma et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Koichi Azuma Japan	42	3.3k	3.0k	1.5k	949	850	266	6.2k
Niels Reinmuth Germany	43	5.0k 1.5×	2.9k 1.0×	2.9k 2.0×	1.5k 1.6×	795 0.9×	196	7.9k
Marie Wislez France	47	4.5k 1.3×	4.1k 1.3×	2.0k 1.3×	958 1.0×	979 1.2×	284	8.1k
Stéphane Champiat France	32	5.4k 1.6×	1.9k 0.6×	883 0.6×	493 0.5×	510 0.6×	130	7.2k
Evan J. Lipson United States	41	5.9k 1.8×	1.6k 0.5×	1.4k 0.9×	642 0.7×	524 0.6×	126	7.7k
Thomas Brunner Germany	43	2.9k 0.9×	1.9k 0.6×	1.5k 1.0×	908 1.0×	658 0.8×	170	5.9k
Christopher Poremba Germany	54	2.5k 0.8×	2.2k 0.7×	3.0k 2.0×	1.8k 1.9×	648 0.8×	166	7.7k
Yutaka Takeda Japan	38	2.0k 0.6×	1.3k 0.4×	1.5k 1.0×	1.2k 1.3×	857 1.0×	311	5.3k
Toshihiko Iizasa Japan	42	2.4k 0.7×	3.3k 1.1×	1.3k 0.9×	608 0.6×	608 0.7×	146	6.3k
Jean‐Christophe Sabourin France	31	2.5k 0.7×	1.0k 0.3×	845 0.6×	680 0.7×	428 0.5×	126	4.2k
Roberto Bianco Italy	49	5.0k 1.5×	3.4k 1.1×	3.7k 2.5×	1.2k 1.3×	534 0.6×	208	8.9k

Countries citing papers authored by Koichi Azuma

Since Specialization

Citations

This map shows the geographic impact of Koichi Azuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koichi Azuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koichi Azuma more than expected).

Fields of papers citing papers by Koichi Azuma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koichi Azuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koichi Azuma. The network helps show where Koichi Azuma may publish in the future.

Co-authorship network of co-authors of Koichi Azuma

This figure shows the co-authorship network connecting the top 25 collaborators of Koichi Azuma. A scholar is included among the top collaborators of Koichi Azuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koichi Azuma. Koichi Azuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ogawa, Eiichi, Motoyuki Kohjima, Toshimasa Koyanagi, et al.. (2025). Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment. Journal of Gastroenterology and Hepatology. 40(10). 2560–2567.

Kanda, Shintaro, Seiji Niho, Takayasu Kurata, et al.. (2025). Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation. Clinical Cancer Research. 31(12). 2317–2326. 1 indexed citations

Kogure, Yoshihito, Hiroya Hashimoto, Haruko Daga, et al.. (2024). Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%. JTO Clinical and Research Reports. 6(3). 100784–100784.

Okazaki, Shinji, et al.. (2024). Evaluation of Corrosion Potential Stability of Stainless Steels in Dilute Electrolyte Solution for Application to a Quasi-Reference Electrode Used in Electrochemical Sensing System. Chemosensors. 13(1). 4–4.

Udagawa, Hibiki, Shingo Matsumoto, Hiroki Izumi, et al.. (2024). Efficacy of immunotherapy in first-line treatment for non-small cell lung cancer with HER2 mutation: Results from LC-SCRUM-Asia.. Journal of Clinical Oncology. 42(16_suppl). 8629–8629. 1 indexed citations

Nishio, Makoto, Shuji Murakami, Hisato Kawakami, et al.. (2024). Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer Research Communications. 4(1). 226–235. 2 indexed citations

Azuma, Koichi, Kenta Murotani, Akihiko Kawahara, et al.. (2024). Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy. Cancer Immunology Immunotherapy. 73(11). 214–214. 1 indexed citations

Matsuo, Norikazu, Koichi Azuma, Kenta Murotani, et al.. (2023). Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors. Thoracic Cancer. 14(15). 1362–1367. 15 indexed citations

Azuma, Koichi, Norikazu Matsuo, Kenta Murotani, et al.. (2023). Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors. Cancer Medicine. 12(19). 19471–19479. 7 indexed citations

10.

Morimoto, Kenji, Tadaaki Yamada, Ryo Sawada, et al.. (2023). Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer. Cancer Immunology Immunotherapy. 72(6). 1699–1707. 5 indexed citations

11.

Miura, Satoru, Yasuhiro Koh, Koichi Azuma, et al.. (2023). Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. BMC Cancer. 23(1). 6–6. 5 indexed citations

12.

Morimoto, Kenji, Ryo Sawada, Tadaaki Yamada, et al.. (2022). A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. JTO Clinical and Research Reports. 3(9). 100388–100388. 5 indexed citations

13.

Tachihara, Motoko, Kayoko Tsujino, Takeaki Ishihara, et al.. (2021). Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Management and Research. Volume 13. 9167–9173. 5 indexed citations

14.

Hayashi, Hidetoshi, Shunichi Sugawara, Yasushi Fukuda, et al.. (2021). A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical Cancer Research. 28(5). 893–902. 49 indexed citations

15.

Tanegashima, Tokiyoshi, Yosuke Togashi, Koichi Azuma, et al.. (2019). Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clinical Cancer Research. 25(15). 4808–4819. 69 indexed citations

16.

Kobayashi, Yoshihisa, Koichi Azuma, Hiroki Nagai, et al.. (2016). Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Molecular Cancer Therapeutics. 16(2). 357–364. 57 indexed citations

17.

Ogawa, Eiichi, Norihiro Furusyo, Eiji Kajiwara, et al.. (2015). Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non‐cirrhotic patients with chronic hepatitis C virus genotype 1b infection. Journal of Gastroenterology and Hepatology. 30(12). 1759–1767. 8 indexed citations

18.

Ota, Keiichi, Koichi Azuma, Akihiko Kawahara, et al.. (2015). Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(17). 4014–4021. 366 indexed citations breakdown →

19.

Ishii, Hidenobu, Koichi Azuma, Kazuko Sakai, et al.. (2015). Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget. 6(31). 30850–30858. 65 indexed citations

20.

Azuma, Koichi, Junji Tsurutani, Kazuko Sakai, et al.. (2011). Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochemical and Biophysical Research Communications. 407(1). 219–224. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact